Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

por Schmid, Ulrike, Weber, Benjamin, Sarr, Celine, Freiwald, Matthias
Publicado 2021

Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis

por Schmid, Ulrike, Liesenfeld, Karl-Heinz, Fleury, Angele, Dallinger, Claudia, Freiwald, Matthias
Publicado 2017

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

por Wind, Sven, Schmid, Ulrike, Freiwald, Matthias, Marzin, Kristell, Lotz, Ralf, Ebner, Thomas, Stopfer, Peter, Dallinger, Claudia
Publicado 2019

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

por Marzin, Kristell, Kretschmar, Gunther, Luedtke, Doreen, Kraemer, Sandrine, Kuelzer, Raimund, Schlenker‐Herceg, Rozsa, Schmid, Ulrike, Schnell, David, Dallinger, Claudia
Publicado 2017

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

por Deterding, Robin, Griese, Matthias, Deutsch, Gail, Warburton, David, DeBoer, Emily M., Cunningham, Steven, Clement, Annick, Schwerk, Nicolaus, Flaherty, Kevin R., Brown, Kevin K., Voss, Florian, Schmid, Ulrike, Schlenker-Herceg, Rozsa, Verri, Daniela, Dumistracel, Mihaela, Schiwek, Marilisa, Stowasser, Susanne, Tetzlaff, Kay, Clerisme-Beaty, Emmanuelle, Young, Lisa R.
Publicado 2021

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

por de Bono, Johann, Lin, Chia-Chi, Chen, Li-Tzong, Corral, Jesus, Michalarea, Vasiliki, Rihawi, Karim, Ong, Michael, Lee, Jih-Hsiang, Hsu, Chih-Hung, Yang, James Chih-Hsin, Shiah, Her-Shyong, Yen, Chia-Jui, Anthoney, Alan, Jove, Maria, Buschke, Susanne, Fuertig, René, Schmid, Ulrike, Goeldner, Rainer-Georg, Strelkowa, Natalja, Huang, Dennis Chin-Lun, Bogenrieder, Thomas, Twelves, Chris, Cheng, Ann-Lii
Publicado 2020